Long-term follow-up data from the monarcHER trial indicated that triple targeting of CDK4/6, HER2, and ER resulted in numerically higher overall survival (OS) in ER-positive, HER2-positive ABC patients compared to those treated with standard regimens, following an extensive treatment strategy [18]. Here, ESR1 is linked to aneurysmal bone cyst.